The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma (Q40220487)

18 September 2017

title

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma (English)

1 reference

18 September 2017

1 reference

1 reference

18 September 2017

Ishii T

1 reference

18 September 2017

Inagaki A

1 reference

18 September 2017

Yano H

1 reference

18 September 2017

Kusumoto S

1 reference

18 September 2017

Ri M

1 reference

18 September 2017

Komatsu H

1 reference

18 September 2017

Iida S

1 reference

18 September 2017

Inagaki H

1 reference

18 September 2017

Ueda R

1 reference

18 September 2017

publication date

12 October 2006

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

page(s)

2162-2168

1 reference

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Establishment of a malignant, epstein-barr-virus (EBV)-negative cell-line from the pleura effusion of a patient with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Hodgkin's disease: establishment and characterization of four in vitro cell lies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404415

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2404415

1 reference

Dimensions Publication ID

18 September 2017

1017583112

0 references

1 reference